Summary The Parasitic Partnering 2007-2012 report provides understanding and access to the parasitic partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in parasitic partnering deals Top parasitic deals by value Deals listed by company A-Z, industry sector, stage of development, technology type Description http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/parasitic-partnering-2007-2012.html The Parasitic Partnering 2007-2012 provides understanding and access to the parasitic partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of parasitic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors parasitic technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner?s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments yellow high heels clauses, the devil is in the detail in terms of how payments are triggered ? contract documents provide this insight where press releases do not. This data driven report contains over 40 links to online copies of actual parasitic deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner?s flexibility on a wide range of important issues, many of which will have a significant impact on each party?s ability to derive value from the deal. The initial chapters of this report provide an orientation of parasitic partnering trends. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in parasitic partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends. Chapter 3 provides an overview of the leading parasitic deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive directory of parasitic partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of parasitic technologies and products. Report scope Parasitic Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access to parasitic trends and structure of deals entered into by leading companies worldwide. This data driven report includes: 6 inch high heels Trends in parasitic dealmaking in the biopharma industry since 2007 Access to summary headline, upfront, milestone and royalty data The leading parasitic deals by value since 2007 In Parasitic Partnering 2007-2012, the available deals are listed by: Headline value Upfront payment value Royalty rate value Company A-Z Industry sector Stage of development at signing Deal component type Technology type Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Benefits Parasitic Partnering 2007-2012 provides the reader with the following key benefits: In-depth understanding of parasitic deal trends since 2007 Access to summary headline, upfront, milestone and royalty data Comprehensive access to over 40 actual parasitic deals entered into by the world?s biopharma companies since 2007 Insight into key deal terms included in contracts, where disclosed Understand the key deal terms companies have agreed in deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Executive Summary Chapter 1 ? Introduction Chapter 2 ? Trends in parasitic partnering 2.1. Introduction 2.2. Parasitic partnering over the years 2.3. Bigpharma parasitic dealmaking activity 2.4. Parasitic partnering by deal type 2.5. Parasitic partnering industry sector 2.6. Parasitic partnering by stage of development 2.7. Parasitic partnering by technology type 2.8. Disclosed financial deal terms for parasitic partnering 2.8.1 Parasitic headline values 2.8.2 Parasitic upfront payments 2.8.3 Parasitic milestone payments 2.8.4 Parasitic royalty rates Chapter 3 ? Leading parasitic deals 3.1. Introduction 3.2. Top parasitic deals by value 3.3. Top parasitic deals involving bigpharma Chapter 4 ? Dealmaking directory 4.1. Introduction 4.2. Company A-Z 4.3. By deal type Asset purchase Bigpharma outlicensing christian louboutin sneakers Co-development Collaborative R&D Co-market Contract service Co-promotion CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Manufacturing Marketing Option Promotion Research Settlement Spin out Sub-license Supply Termination 4.4. By industry sector Academic Bigpharma Biotech Drug delivery Medical device Diagnostic Generic pharma Government Non-profit Pharmaceutical Research tools Services Specialty pharma 4.5. By stage of development Discovery Pre-clinical Phase I Phase II Phase III Registration Marketed 4.6. By technology type Analysis Animal models Assays Bioinformatics Biological compounds Biomarkers Biomaterials Cell culture Cell therapy Clinical testing Diagnostic - companion Devices Diagnostics Discovery tools DNA probes Drug delivery Enabling technology Epigenetics Equipment Facilities Gene therapy Genomics Imaging Industrial chemicals In vitro models Monoclonal antibodies Nanotechnology Oligonucleotide Peptides Personalised medicine Processes Proteomics Radio/Chemo-therapy Recombinant DNA Research services Research supplies RNA therapeutics Screening Small molecules Stem cells Vaccines Chapter 5 ? Partnering resource center 5.1. Online partnering 5.2. Partnering events 5.3. Further reading on dealmaking Appendices Appendix 1 ? Deal type definitions About Wildwood Ventures Current Partnering Current Agreements Recent titles from CurrentPartnering Order Form ? Reports Table of Figures Figure 1: Parasitic partnering since 2007 Figure 2: Bigpharma ? top 50 ? parasitic deals 2007 to 2011 Figure 3: Bigpharma parasitic deal frequency ? 2007 to 2011 Figure 4: Parasitic partnering by deal type since 2007 Figure 5: Parasitic partnering by industry sector since 2007 Figure 6: Parasitic partnering by stage of development since 2007 Figure 7: Parasitic partnering by technology type since 2007 Figure christian louboutin 8: Parasitic deals with a headline value Figure 9: Parasitic deals with upfront payment values Figure 10: Parasitic deals with shoes for women milestone payments Figure 11: Parasitic deals with royalty rates, % Figure 12: Top parasitic deals by value since 2007 Figure 13: Top parasitic deals signed by bigpharma value since 2007 Figure 14: Online partnering resources Figure 15: Forthcoming partnering events Figure 16: Deal type definitions